Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 18 and up

Lower local anesthetic concentration and rebound shoulder pain after shoulder arthroplasty

Official title: Effect of Local Anesthetic Concentration on Rebound Pain: A Randomized Control Study

Run by University of Virginia · NCT07146685 · Data updated 2026-11-12

This study tests whether using a lower concentration of local anesthetic in a nerve block reduces rebound pain 24 hours after shoulder replacement surgery.

Quick facts

PhasePhase 4
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment10 (estimated)
SponsorUniversity of Virginia
Academic / other
Locations1 site (Charlottesville, Virginia)
StatusRecruiting
StartedMay 13, 2026
Main results expectedJanuary 28, 2028
Study endsJanuary 28, 2029
Registry record updatedSeptember 9, 2026
Trial IDNCT07146685 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18 years and older undergoing anatomic or reverse total shoulder arthroplasty.

Probably not a fit

Patients with complex regional pain syndrome, chronic daily opioid use, significant respiratory disease, or other listed exclusions may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, phase 4 trial compares different concentrations of local anesthetic delivered via brachial plexus block for adults undergoing anatomic or reverse total shoulder arthroplasty. The goal is to see if a lower concentration leads to lower rebound pain scores at 24 hours postoperatively. Bupivacaine is the local anesthetic used, and participants are assigned to different concentration levels. Primary care sites are limited to UVA Health, with broad eligibility for adults without certain chronic pain conditions or respiratory issues. The study aims to inform optimal dosing to balance analgesia with rebound pain risk.

Why it matters

Potential benefit: If successful, patients may experience less rebound pain after shoulder replacement, potentially improving comfort and recovery.

How similar studies have gone: Previous work in regional anesthesia has explored concentration effects, with mixed results; this trial contributes targeted data for shoulder arthroplasty.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Total shoulder replacement patients (anatomic and reverse)
* Adult patients (greater than or equal to 18 years)
* Any gender
* Any race

Exclusion Criteria:

* \- Chronic Pain diagnoses including:
* substance/opioid use disorder
* complex regional pain syndromes
* fibromyalgia
* Daily persistent opioid use spanning 3 months prior to surgery date
* Allergy to local anesthetics or NSAIDS
* Respiratory pathologies including:
* CPAP- non-compliant / untreated obstructive sleep apnea
* COPD
* Restrictive lung disease (pulmonary fibrosis, interstitial pneumonia, etc)
* Contralateral diaphragm dysfunction
* BMI \> 40
* Ipsilateral extremity pre-existing nerve injury
* GFR \< 60
* NSAID contraindications
* Inability to follow up
* Revision surgery
* Patients requesting block as primary (avoidance of general anesthesia)
* Need or request for brachial plexus catheter or liposomal bupivacaine
* Vulnerable populations (pregnancy, incarceration, etc)
* non-English speaking

Where it's running

  • UVA Health
    Charlottesville, Virginia, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.